Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
Microbial Cell · 05.12.2022 · 9 (12) · 190-194
DOI: 10.15698/mic2022.12.787 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Cell, online erschienen am 05.12.2022. Verfasst von Safae Terrisse und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Hôpital Saint-Louis, Paris, France. Die Arbeit wurde bisher 34-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Prostate cancer (PC) can be kept in check by androgen deprivation therapy (ADT, usually with the androgen synthesis inhibitor abiraterone acetate or the androgen receptor antagonist such as enzalutamide) until the tumor evolves to castration-resistant prostate cancer (CRPC). The transition of hormone-sensitive PC (HSPC) to CPRC has been explained by cancer cell-intrinsic resistance mechanisms. Recent data indicate that this transition is also marked by cancer cell-extrinsic mechanisms such as the failure of ADT-induced PC immunosurveillance, which depends on the presence of immunostimulatory bacteria in the gut. Moreover, intestinal bacteria that degrade drugs used for ADT, as well as bacteria that produce androgens, can interfere with the efficacy of ADT. Thus, specific bacteria in the gut serve as a source of testosterone, which accelerates prostate cancer progression, and men with CRPC exhibit an increased abundance of such bacteria with androgenic functions. In conclusion, the response of PC to ADT is profoundly influenced by the composition of the microbiota with its immunostimulatory, immunosuppressive and directly ADT-subversive elements.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology, Hôpital Saint-Louis, Paris, France.
- INSERM U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France.
- University Paris Saclay, Gif-sur-Yvette, France.
- Gustave Roussy, ClinicObiome, Villejuif, France.
- Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
- Equipe labellisée par la Ligue contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Inserm U1138, Centre de Recherche des Cordeliers, Paris, France.
Zitieren
APA
Terrisse, S., Zitvogel, L., & Kroemer, G. (2022). Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy. Microbial Cell, 9(12), 190-194. https://doi.org/10.15698/mic2022.12.787
Vancouver
Terrisse S, Zitvogel L, Kroemer G. Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy. Microbial Cell. 2022;9(12):190-194. doi:10.15698/mic2022.12.787
BibTeX
@article{Terrisse2022,
author = {Terrisse, Safae and Zitvogel, Laurence and Kroemer, Guido},
title = {Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy},
journal = {Microbial Cell},
year = {2022},
volume = {9},
number = {12},
pages = {190--194},
doi = {10.15698/mic2022.12.787}
}
EUVIMED